From a statistical perspective, the frequency of somatic mutations in TGF-β ligands and receptors and Smad genes is less than 1.0% (the cumulative pathway alteration rate is about 5%) in the TCGA cohort of HCC samples. This evidence concerns the gene TGFB1 and hepatocellular carcinoma.